SCHEMBL5857543

SCHEMBL5857543

COC(=O)[C@]1(C)OC[C@H](c2ccc(Cc3nc(-c4ccccc4)oc3C)cc2)CO1

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 16/20 0.67
PPARG P37231 14/20 0.66
KDM4E B2RXH2 1/20 0.45
FFAR1 O14842 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5857394 0.90 PPARA (0.80) PPARAPPARGKDM4E
SCHEMBL5856192 0.90 PPARA (0.83) PPARAPPARGKDM4E
SCHEMBL5857005 0.90 PPARA (0.82) PPARAPPARGKDM4E
SCHEMBL4248018 0.87 PPARA (0.66) PPARAPPARGFFAR1
SCHEMBL4243392 0.87 PPARA (0.66) PPARAPPARGFFAR1
SCHEMBL4243491 0.86 PPARG (0.67) PPARAPPARG
SCHEMBL4252906 0.86 PPARG (0.67) PPARAPPARG
SCHEMBL5857999 0.85 PPARA (0.63) PPARAPPARGKDM4EFFAR1
SCHEMBL5858210 0.83 PPARA (0.83) PPARAPPARG
SCHEMBL12802663 0.83 PPARA (0.65) PPARAPPARGKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144906-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-12-05 US disclosed
US-7030143-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-18 US disclosed
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 US disclosed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP disclosed
US-6998412-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-02-14 US disclosed
US-20050009785-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2005-01-13 US disclosed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 US disclosed
US-20040162325-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2004-08-19 US disclosed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US disclosed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009785-A1 Heterocyclic compounds LIPC, GPR119, APOB PPARA 464/4885PPARG 393/4885KDM4E 1600/4885
US-20050009892-A1 Heterocyclic compounds GPR119, LIPC, LIPE PPARA 579/4885PPARG 603/4885KDM4E 1141/4885
US-20040162325-A1 Heterocyclic compounds LIPE, GPR119, LIPC PPARA 660/4885PPARG 701/4885KDM4E 1321/4885
US-20030166697-A1 Heterocyclic compounds LIPE, GPR119, LIPC PPARA 660/4885PPARG 701/4885KDM4E 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.